Last October, we published a table on mood stabilizer side effects that raised an understandable alarm among astute readers. The table, which was based on a 2020 meta-analysis, suggested that aripiprazole (Abilify) has a greater chance of causing weight gain than quetiapine (Seroquel). What the table failed to specify was that the figures were based on long-term maintenance studies. In the short-term trials, quetiapine ranked right behind olanzapine for its propensity to increase BMI, while aripiprazole had a non-significant effect.
Mood stabilizers are intended for long-term use, which is why we decided to focus on the long-term data. However, there are far more short-term trials than long-term ones, so we are less confident in these results. In this meta-analysis, the difference between aripiprazole and quetiapine was based on only 3 bipolar maintenance trials (n = 773). Things become more certain when we expand that population to all psychiatric patients, as Maarten Bak and colleagues did in 2014 (Bak M et al, PLoS One 2014;9(4):e94112). Pulling together 11 trials that lasted at least 9 months, Bak found similar rates of weight gain for aripiprazole and quetiapine, both in terms of the rate of clinically significant (> 7%) weight gain (1 in 5 for both meds, compared to 1 in 25 for placebo) and the absolute increase in BMI.
Look out for long-term weight gain in your patients. Most of what we know about this side effect comes from short-term trials, and those may not tell the whole story.
Behavioral activation came about in the 1990’s as a challenge to the CBT model of depression. The basic strategy behind this therapy blends well with brief medication visits, and we explain how to use it in this professional guide.
1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...